To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00141245
• Date of registration: 30/08/2005
• Prospective Registration: No
• Primary sponsor: Pfizer
• Public title: To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
• Scientific title: Pregabalin Open-Label, Multicenter Add-On Trial Following a 4-Day Double-Blind Transition Period to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
• Date of first enrolment: October 1998
• Target sample size: 325
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00141245
• Study type: Interventional
• Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
• Phase: Phase 3

Countries of recruitment

Australia, Austria, Belgium, Finland, France, Germany, Italy, Netherlands, South Africa, Spain, Sweden, Switzerland, United Kingdom

Contacts

• Name: Pfizer CT.gov Call Center
• Affiliation: Pfizer

Key inclusion & exclusion criteria

Inclusion Criteria:

- Must have met the inclusion criteria for preceding double-blind study

- Have received double-blind study medication and wish to receive open-label
pregabalin.

Exclusion Criteria:

- Cannot have absence seizures



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Seizure Disorder, Partial

Intervention(s)

Drug: Pregabalin

Primary Outcome(s)

Safety Efficacy

Secondary ID(s)

1008-012

Source(s) of Monetary Support

Please refer to primary and secondary sponsors